<DOC>
	<DOCNO>NCT02063555</DOCNO>
	<brief_summary>This Phase 1 , randomize , control , double-blind , multiple-dose , dose-ranging study DAR 901 , ( inactivated whole cell mycobacterial vaccine ) conduct HIV negative HIV positive adult previously vaccinate BCG . The goal trial determine safety , tolerability , immunogenicity multiple dos vaccine different dose level , range 0.1 1 mg .</brief_summary>
	<brief_title>Phase I Trial DAR-901</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>All subject : age 1865 , prior BCG vaccine ( scar ) 56 HIV negative subject : negative ELISA HIV ( 48 subject negative IGRA , 8 subject positive IGRA ) 21 HIV positive subject : positive ELISA HIV , ART ( 13 subject negative IGRA , 8 subject positive IGRA ) pregnancy , positive serology hepatitis B C , active tuberculosis immunosuppression , severe medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>BCG</keyword>
	<keyword>HIV</keyword>
	<keyword>TB Vaccines</keyword>
</DOC>